Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements.
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Bevantolol (Primary)
- Indications Huntington's disease
- Focus Proof of concept; Therapeutic Use
- Sponsors SOM Biotech
- 17 Jul 2018 According to a SOM Biotech media release,Status changed from not yet recruiting to recruiting.
- 28 Jun 2018 Status changed from planning to not yet recruiting.
- 13 Oct 2017 New trial record